These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24997757)

  • 21. Gestodene-containing contraceptives.
    Kuhl H; Jung-Hoffmann C; Wiegratz I
    Clin Obstet Gynecol; 1995 Dec; 38(4):829-40. PubMed ID: 8616979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
    Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
    Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
    Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
    Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study.
    Merz M; Grunert J
    Womens Health (Lond); 2014 Jan; 10(1):37-43. PubMed ID: 24328597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
    Trapnell CB; Connolly M; Pentikis H; Forbes WP; Bettenhausen DK
    Ann Pharmacother; 2007 Feb; 41(2):222-8. PubMed ID: 17284510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
    Uchikova E; Terzhumanov R; Milchev N; Iacheva T
    Akush Ginekol (Sofiia); 2004; 43(6):19-23. PubMed ID: 15669648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
    Kuhnz W; Sostarek D; Gansau C; Louton T; Mahler M
    Am J Obstet Gynecol; 1991 Sep; 165(3):596-602. PubMed ID: 1892184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
    Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females.
    Richter WH; Koytchev R; Kirkov V; Merki G; Colli E; Regidor PA
    Contraception; 2020 Feb; 101(2):137-143. PubMed ID: 31758920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
    Täuber U; Kuhnz W; Hümpel M
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1414-20. PubMed ID: 2220966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
    Garg V; van Heeswijk R; Yang Y; Kauffman R; Smith F; Adda N
    J Clin Pharmacol; 2012 Oct; 52(10):1574-83. PubMed ID: 22039291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.
    Palovaara S; Kivistö KT; Tapanainen P; Manninen P; Neuvonen PJ; Laine K
    Br J Clin Pharmacol; 2000 Oct; 50(4):333-7. PubMed ID: 11012556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.